AMT Makes Advance in the Development of its Gene Therapy for Hemophilia B
Company Accesses Technology to Prevent Immune Response
11-Jun-2008 -
Amsterdam Molecular Therapeutics announced that it obtained a license from 'TIGET' San Raffaele Telethon Institute For Gene Therapy, Italy, to use their micro-RNA technology to prevent immune responses against gene therapy for Hemophilia B. This technology enables AMT to accelerate the ...
collaborations
Expression
gene therapy
+4